Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.
JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.
Plasma cells (PCs) are the main producers of antibodies and have context-dependent roles in tumor immunity. In this issue of Cancer Cell, Gao et al. report…
Fred Hutch graduate student Adam Nguyen has won a F31 training award from the NIH to study a complex molecule called Tie2 that aids and…
Gao et al. show that the plasma cells (PCs) can be recruited to glioblastoma stem cell (GSC) niches via the CCL2-CCR2 chemokine program and promote glioblastoma…
ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.
Presenters: Daniella Landau, CEO, MyCareCompass Health, Linda Fleisher, PhD, MPH, Fox Chase Cancer Center/Temple Health Conference: ASCO Direct™ Washington DC 2024
This study analyzes the characteristics and outcomes of adults with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA-sAML). This…
A pair of studies by a team of Fred Hutch public health researchers found that a surprising number of people use alcohol and/or cannabis after…
Despite improvements in recruitment of Latina medical students, the percentage of Latina physicians has remained stagnant, suggesting unique barriers to retention and career advancement. This…
The first stage of a phase 2 trial evaluating neoadjuvant SHR-A1811 in breast cancer meets its primary end point of ORR.